Scynexis (SCYX) Share-based Compensation (2013 - 2026)
Scynexis' (SCYX) quarterly Share-based Compensation came in at $600000.0 in Q2 2026, down 83.63% on a YoY basis from $3.7 million in Q2 2025, and down 82.95% quarter-over-quarter from $3.5 million in Q1 2026.
Analysis
Scynexis (SCYX) Share-based Compensation (2013 - 2026) Analysis & Trends
Scynexis (SCYX) has reported Share-based Compensation for 14 consecutive years, with $600000.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Share-based Compensation fell 83.63% year-over-year to $600000.0; the trailing twelve-month figure through Jun 2026 stood at $2.8 million (down 24.42% YoY), and the FY2025 full-year result was $2.9 million, down 13.33% from the prior year.
- Share-based Compensation slipped to $600000.0 in Q2 2026 per SCYX's latest filing, from $3.5 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $3.7 million in Q2 2025 and bottomed at $454000.0 in Q4 2022.
- Historically, Share-based Compensation has averaged $2.0 million across 5 years, with a median of $2.0 million in 2023.
- The widest YoY moves for Share-based Compensation: up 254.17% in 2022, down 87.63% in 2022.
- Over 5 years, Share-based Compensation stood at $454000.0 in 2022, then rose by 15.42% to $524000.0 in 2023, then jumped by 80.53% to $946000.0 in 2024, then decreased by 26.0% to $700000.0 in 2025, then dropped by 14.29% to $600000.0 in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $600000.0, $3.5 million, and $700000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 247.00 Mn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 231.00 Mn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 108.10 Mn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 243.00 Mn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 120.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 86.63 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 77.40 Mn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | 83.34 Mn |
| 10 | Scynexis | 58.41 Mn | -56.29 Mn | - | 600,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 600,000.00 |
| Mar 31, 2026 | 3.52 Mn |
| Dec 31, 2025 | 700,000.00 |
| Sep 30, 2025 | 3.63 Mn |
| Jun 30, 2025 | 3.66 Mn |
| Mar 31, 2025 | 3.54 Mn |
| Dec 31, 2024 | 946,000.00 |
| Sep 30, 2024 | 2.91 Mn |
| Jun 30, 2024 | 2.84 Mn |
| Mar 31, 2024 | 2.72 Mn |
| Dec 31, 2023 | 524,000.00 |
| Sep 30, 2023 | 1.96 Mn |
| Jun 30, 2023 | 1.97 Mn |
| Mar 31, 2023 | 1.96 Mn |
| Dec 31, 2022 | 454,000.00 |
| Sep 30, 2022 | 2.13 Mn |
| Jun 30, 2022 | 1.10 Mn |
| Mar 31, 2022 | 922,000.00 |
| Sep 30, 2021 | 600,000.00 |
| Jun 30, 2021 | 542,000.00 |